Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + IPATASERTIB for glioma

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 8 Jun 2015: Trial registered, NCT02465060
  2. 17 Aug 2015: Trial started, NCT02465060

The trials

NCT02465060: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

State
Under way
Phase
Phase 2
People
6,452 planned
Started
17 Aug 2015
Primary completion
31 Dec 2027
Arms
Subprotocol Z1K (AKT mutation)
Results
None posted
  1. 8 Jun 2015: Trial registered
  2. 17 Aug 2015: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.